Get the Daily Brief
Latest Biotech News
Merck taps Mayo Clinic data and AI for drug discovery
Merck announced a research-and-development collaboration with the Mayo Clinic to combine clinical and genomic datasets from the Mayo Clinic Platform with Merck’s AI-enabled virtual cell...
Lilly pays $100M upfront for CSL’s IL‑6 antibody rights
Eli Lilly agreed to license development rights from CSL for the IL‑6–blocking antibody clazakizumab outside CSL’s retained indication, paying $100 million in upfront consideration with additional...
J&J commits $1B to cell therapy manufacturing hub in Pennsylvania
Johnson & Johnson announced a more-than-$1 billion investment to build a cell therapy manufacturing facility in Pennsylvania, expanding the company’s clinical- and commercial-scale capacity for...
Korsana raises $175M to pursue anti‑amyloid Alzheimer antibody
Korsana Therapeutics launched with $175 million in venture backing to develop KRSA‑028, an anti‑amyloid antibody aimed at Alzheimer’s disease; the financing was led by Wellington, Sanofi Ventures...
Stress protein LCN2 helps tumors evade immunity – NYU preclinical work
Researchers at NYU Langone identified lipocalin 2 (LCN2) as a major effector of the integrated stress response (ISR) that enables lung and pancreatic tumors to evade immune attack. Published in...
PSBench: 1.4M validated protein models to sharpen structure AI
University of Missouri researchers released PSBench, the world’s largest annotated collection of protein structure models—about 1.4 million entries—with expert quality assessments to benchmark and...
AI reprograms yeast to cut protein‑drug costs
MIT chemical engineers unveiled an AI‑driven method that programs industrial yeast to boost production of therapeutic proteins, promising lower manufacturing costs and faster process development...
FDA reverses, will review Moderna flu shot: PDUFA set for Aug. 5
The FDA abruptly reversed course and agreed to review Moderna’s mRNA influenza vaccine candidate mRNA-1010, setting a PDUFA target date of Aug. 5, 2026. The agency moved from a refusal-to-file...
Compass scores second phase III: Psilocybin heads toward NDA
Compass Pathways reported a second positive Phase III trial for COMP360, its synthetic psilocybin therapy for treatment‑resistant depression, and said it will move toward a rolling NDA submission....
Merck partners with Mayo Clinic: AI and clinical genomics to drive discovery
Merck signed a collaboration with the Mayo Clinic to combine clinical and genomic datasets, AI tools and advanced analytics to accelerate drug discovery across inflammatory and immune‑mediated...
Gilead pays into synthetic‑lethality pipeline: $1.53B deal for Genhouse MAT2A asset
Gilead Sciences licensed a clinic‑ready MAT2A inhibitor from Suzhou‑based Genhouse Bio in a deal that could total up to $1.53 billion. The agreement gives Gilead access to GH31, a candidate...
Lilly buys rights to CSL’s IL‑6 antibody: $100M upfront to expand inflammation lineup
Eli Lilly paid $100 million up front to license clazakizumab, an IL‑6–blocking monoclonal antibody from CSL, securing rights to develop the drug in indications outside CSL’s retained kidney...
Korsana launches with $175M to chase Alzheimer’s antibodies
Korsana Therapeutics emerged from Paragon Therapeutics with $175 million in venture backing to advance an anti‑amyloid antibody program, KRSA‑028, targeting Alzheimer’s disease. The financing was...
Sensei rescues Faeth, gains phase II oncology asset and $200M placement
Sensei Biotherapeutics announced a merger/acquisition of Faeth Therapeutics that brings Faeth’s phase II PI3K/AKT/mTOR combination asset Piktor into Sensei’s pipeline and was executed alongside a...
J&J doubles down on cell therapy: $1B+ manufacturing site planned in Pennsylvania
Johnson & Johnson announced a plan to invest more than $1 billion to build a cell therapy manufacturing facility in Pennsylvania as part of a wider effort to scale advanced‑therapy production. The...
Ocular’s Axpaxli beats low‑dose Eylea in Phase III – market questions follow
Ocular Therapeutix reported that its intravitreal TKI hydrogel Axpaxli met the superiority primary endpoint versus a low‑dose comparator of Regeneron’s Eylea in the Sol‑1 Phase III trial for wet...
AI cuts protein drug development costs: MIT model speeds yeast engineering
MIT chemical engineers unveiled an AI‑driven method to program industrial yeast strains for protein production that substantially reduces time and cost in biopharmaceutical manufacturing. The...
AI decodes yeast DNA: manufacturers chase cheaper protein drugs
MIT chemical engineers published a study introducing an AI-driven method that programs industrial yeast to produce biopharmaceutical proteins faster and at lower cost. The team trained large...
FDA backtracks: Moderna’s mRNA flu shot put back on review track
The FDA reversed an earlier refuse‑to‑file decision and agreed to review Moderna’s revised mRNA influenza vaccine submission after the company amended its filing and the agency held an internal...
Compass nears FDA bid after second pivotal psilocybin victory
Compass Pathways reported a second positive Phase III trial for its synthetic psilocybin candidate COMP‑360 in treatment‑resistant depression, enabling the company to prepare a rolling NDA and...